+44 20 8123 2220
info@marketpublishers.com

Global Bispecific Antibody Market & Clinical Pipeline Insight 2020

https://marketpublishers.com/r/G2A67CA05CAEN.html
Date: July 2016
Pages: 213
Price: US$ 2,400.00 (Single User License)
ID: G2A67CA05CAEN

Abstracts

Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

With revolutionization in the medicinal sector and more of inclination towards personalized therapy, the medical world is also witnessing the emergence of advanced analogues of monoclonal antibodies called as Bispecific monoclonal antibodies. As the name signifies the molecules possess “dual specificity”.

The licensing of the first monoclonal antibody for clinical use dates back to 1986, since then almost 70 therapeutic monoclonal antibodies (MAbs) have been approved throughout the world along with several antibody-related products (e.g., Fc-fusion proteins) making MAbs and related products a dominant component of the biopharmaceutical market, generating revenues of several billion dollars. The approach and specificity of these molecules is no doubt gaining the interest of numerous scientists, pharma, biotechnological companies, research laboratories as well as academic institutions adding to everyday improvement in the biological, physical, chemical and bio-chemical aspects of its action and functioning making the segment more interesting.

With coming of the new technology and more of research in this segment around 50 different formats of bispecific antibody production have been discovered and patented by big pharma ventures. Production of CrossMabs, Diabodies, Nano bodies, Bispecific T-cell engager antibodies (BiTEs), dual-variable-domain immunoglobulin (DVD-Ig™) are some of the most employed and significant techniques. These molecules two distinct binding specificities also have shown great potential for a wide range of clinical applications which includes targeting agents for in vitro and in vivo immunodiagnosis, therapy and for improving immunoassays. They have proven themselves as promising

+44 20 8123 2220
info@marketpublishers.com

molecules for targeting cytotoxic effector cells, delivering radionuclides, toxins or cytotoxic drugs to specific targets, particularly tumor cells. Much more stills needs to be unravelled making this sector a huge matter of interest.

The applications of these molecules are as wide as the approaches of their development. They are being developed to tackle the plethora of diseases ranging from different cancers (Prostate, Breast, Colon, Squamous cell carcinomas) to non-oncological segment including various chronic inflammatory diseases such as Rheumatoid arthritis etc. Their multifactorial approach to deal with a disease is making them for acceptable as a player of future health market as most of the disease are multifactorial and require treatment with a combination of drugs. Development of single molecule with all the desirable approaches is no doubt a great driving factor when seen from patient compliance view.

Moreover, it has been observed that a single molecule can heal more than one disease and nothing more can than this factor make a pharmaceutical venture to invest in Research and Development of this wonder molecule. As developing and patenting a single agent for multiple diseases is for sure a matter of huge profit for them. Following years of research and development (R&D), the first trifunctional antibody Catumaxomab (Removab®) was approved in 2009. Another BsAb Blinatumomab (Blincyto) marketed by Amgen entered the market in December 2014 and several more AMG-110, ABT-122, SAR156597 etc. are in clinical trials.

The pipeline of bispecific antibodies seems to be extremely rich with more than 100 proposed drugs in trials with most of them being in their Preclinical trials. Most of these drugs are propagated to enter the market in the coming 5 to 6 years, occupying a huge segment of health market. The phase is stipulated to swirl the medical world as this will for sure lead to more investments in this direction. The major challenges associated are the monetary restrictions for both the manufacturers as well as the consumers. Everything novel in medical sector comes with a huge price tag and this was proved by extensively costly therapy of Blinatumomab, which costed $178,000 per two-cycles making it unachievable for the common patients. Other associated challenges include stringent regulatory guidelines, conduction of clinical trials and long duration of research associated.

This report extensively covers the major events from the infancy to the present status of the Bispecific antibodies. It gives a purposeful outlook of the bright future of this wonder molecule which is sure to establish its niche in the coming years; as the abnormalities it is proposed to deal with along with the ways to mitigate them is proportionately too high

+44 20 8123 2220
info@marketpublishers.com

to be ignored.

“Global Bispecific Antibody Market & Clinical Pipeline Insight 2020” Report Highlights:

Overview of Bispecific Antibody

Mechanism of Action of Bispecific Antibody

Design & Engineering of Bispecific Antibodies

Applications of Bispecific Antibodies

Global Bispecific Antibodies Clinical Pipeline by Company, Indication & Phase

Global Bispecific Antibodies Clinical Pipeline: 123 Bispecific Antibodies

Marketed Bispecific Antibodies: Blinatumomab (Blincyto) & Catumaxomab (Removab)

+44 20 8123 2220
info@marketpublishers.com

Contents

+44 20 8123 2220
info@marketpublishers.com

+44 20 8123 2220
info@marketpublishers.com

13. COMPETITIVE LANDSCAPE

+44 20 8123 2220
info@marketpublishers.com

List Of Figures

LIST OF FIGURES

+44 20 8123 2220
info@marketpublishers.com

List Of Tables

LIST OF TABLES

COMPANIES MENTIONED

Ablynx
Adimab
Affimed Therapeutics
Amgen
AstraZeneca (MedImmune)
Chugai Pharmaceutical
Eli Lilly
EMD Serono
Emergent BioSolutions
Genentech
Genmab
Immunomedics
Jounce Therapeutics
MacroGenics
Merus
Neovii Biotech
NovImmune SA
OncoMed Pharmaceuticals
Pieris
Regeneron Pharmaceuticals
Roche
Sanofi

+44 20 8123 2220
info@marketpublishers.com

I would like to order

Product name: Global Bispecific Antibody Market & Clinical Pipeline Insight 2020
Product link: https://marketpublishers.com/r/G2A67CA05CAEN.html
Price: US$ 2,400.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/G2A67CA05CAEN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

**All fields are required

Custumer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970